Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer
Christian F. Singer(Comprehensive Cancer Center Vienna), Michael Gnant(Austrian Breast & Colorectal Cancer Study Group), Florian Fitzal, Martin Filipits(University of Vienna), Guenther G. Steger(Mount Vernon Hospital), Yen Y. Tan(Comprehensive Cancer Center Vienna), Rupert Bartsch(Universitätszahnklinik Wien), Farid Moinfar(AGO Austria), Daniel Egle(Innsbruck Medical University), Margaretha Rudas(Comprehensive Cancer Center Vienna), Ruth Exner(Comprehensive Cancer Center Vienna), Christine Gruber(Central Institution for Meteorology and Geodynamics), Reiner Angelika(Donauspital), Michael Seifert(Zimmer Biomet (Germany)), Marija Balić(University of Pittsburgh), Edgar Petru(Medical University of Graz), Kristina A. Tendl(Medical University of Vienna), David Fuchs(Johannes Kepler University of Linz), Zsuzsanna Bagó-Horváth(Comprehensive Cancer Center Vienna)
Cited by 61
Related Papers
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Breast cancer
|The Lancet|2016|2.3k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
|Journal of Clinical Oncology|2010|1.6k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k